Health Canada has granted approval for Biogen’s Skyclarys (omaveloxolone) to treat Friedreich’s ataxia (FA), a rare ... as the sole treatment in the country targeting the underlying mechanisms of FA.

As the only approved treatment to address disease progression, SKYCLARYS addresses a long-standing gap in the care of Canadians living with Friedreich’s ataxia Friedreich’s ataxia is a rare, ...

The biological mechanisms underlying these symptoms are still not fully ... along with gene expression linked to ataxia telangiectasia, impaired cognitive function, and neuronal dysfunction. Surviving ...